Biotechnology (89) | Severance Agreements (89)

Browse by Company

Recent Contracts

Form of Executive Severance Agreement (IRONWOOD PHARMACEUTICALS INC, Filed With SEC on December 1, 2021)
Amended and Restated Severance Benefits Plan (Calithera Biosciences, Inc., Filed With SEC on November 9, 2021)
Turning Point Therapeutics, Inc. Severance Benefit Plan, as amended (C-Suite) May 4, 2021 (Turning Point Therapeutics, Inc., Filed With SEC on August 9, 2021)
Amended and Restated Severance Benefit Plan Eligibility Notice, dated as of June 1 (ARENA PHARMACEUTICALS INC, Filed With SEC on August 5, 2021)
Severance Agreement, dated July 20, 2021, between the Registrant and Doug Doerfler (MAXCYTE, INC., Filed With SEC on July 26, 2021)
Severance Agreement, dated January 11, 2021, between the Registrant and Brad Calvin (MAXCYTE, INC., Filed With SEC on July 26, 2021)
Severance Agreement, dated January 21, 2021, between the Registrant and Amanda Murphy (MAXCYTE, INC., Filed With SEC on July 26, 2021)
Participation Agreement of Mr. Michael A. Carr under the 2021 Executive Severance Plan (Calyxt, Inc., Filed With SEC on July 15, 2021)
Second Amended and Restated Executive Severance Agreement, dated June 22, 2021, between Ironwood Pharmaceuticals, Inc. and Thomas McCourt (IRONWOOD PHARMACEUTICALS INC, Filed With SEC on June 24, 2021)
Severance policies applicable to Robert Morales, Vice President, Finance and Controller, and interim principal financial and accounting officer (Acorda Therapeutics, Filed With SEC on May 12, 2021)